[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585951":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":92,"collaborators":95,"id":102,"slug":103,"hasResults":104,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":104,"sex":110,"minAge":111,"maxAge":25,"enrollmentInfo":112,"targetDuration":25,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":59,"whyStopped":25,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":136},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"aDBS group","EXPERIMENTAL","65 patients with Parkinson's disease will receive adaptive DBS.",[13],"Other: Adaptive DBS",{"label":15,"type":16,"description":17,"interventionNames":18},"cDBS group","ACTIVE_COMPARATOR","65 patients with Parkinson's disease will receive continue DBS.",[19],"Other: Continue DBS",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Adaptive DBS","The Medtronic Percept device will be activated with the aDBS functionality. Participant will receive adaptive DBS.",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Continue DBS","The Medtronic Percept device will be equipped with aDBS functionality (to maintain the blinding of the allocation), but this functionality will remain inactive. Participant will receive continue DBS.",[15],[31],{"name":32,"affiliation":33,"role":34},"Martijn Beudel, MD, PhD","Amsterdam UMC","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"M. Beudel, MD, PhD","CONTACT","+31 20 566 9111","closepd@amsterdamumc.nl",[42,58,70,81],{"facility":43,"status":44,"city":45,"state":25,"zip":25,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"UZ Leuven","NOT_YET_RECRUITING","Leuven","Belgium","BE",{"type":49,"coordinates":50},"Point",[51,52],4.70093,50.87959,{"lat":52,"lon":51},[55],{"name":56,"role":57,"phone":25,"phoneExt":25,"email":25},"B. Swinnen, MD, PhD","SUB_INVESTIGATOR",{"facility":33,"status":59,"city":60,"state":25,"zip":25,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":67,"contacts":68},"RECRUITING","Amsterdam","Netherlands","NL",{"type":49,"coordinates":64},[65,66],4.88969,52.37403,{"lat":66,"lon":65},[69],{"name":32,"role":34,"phone":25,"phoneExt":25,"email":25},{"facility":71,"status":44,"city":72,"state":25,"zip":25,"country":61,"countryCode":62,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Maastricht UMC+","Maastricht",{"type":49,"coordinates":74},[75,76],5.68889,50.84833,{"lat":76,"lon":75},[79],{"name":80,"role":57,"phone":25,"phoneExt":25,"email":25},"M.L.F. Janssen, MD, PhD",{"facility":82,"status":44,"city":83,"state":25,"zip":25,"country":61,"countryCode":62,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"HagaZiekenhuis","The Hague",{"type":49,"coordinates":85},[86,87],4.29861,52.07667,{"lat":87,"lon":86},[90],{"name":91,"role":57,"phone":25,"phoneExt":25,"email":25},"M.F. Contarino, MD, PhD",{"type":34,"investigatorFullName":93,"investigatorTitle":94,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"dr. Martijn Beudel","Principal Investigator",[96,97,99],{"name":82,"class":6},{"name":98,"class":6},"Maastricht University Medical Center",{"name":100,"class":101},"Universitair Ziekenhuis Leuven","UNKNOWN","100585951","adaptive-vs-continuous-subthalamic-nucleus-deep-brain-stimulation-in-parkinsons-disease-100585951",false,"NCT06909045","Adaptive vs. Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease","Randomized Controlled Trial Comparing Adaptive Versus Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease","CLOSE-PD","Inclusion Criteria:\n\n* Diagnosis of idiopathic PD based on the UK Brain Bank criteria (Hughes et al. 1992);\n* Age older than 18 years;\n* Previous implantation of Medtronic PerceptTM PC\u002FRC DBS electrodes bilateral targeting the STN;\n* Optimal contact point compatible with aDBS in at least one STN;\n* Reliable beta peak in at least one STN;\n* Able to provide informed consent and comply with the study protocol;\n* Understand the Dutch language.\n\nExclusion Criteria:\n\n* Legally incompetent adults;\n* Patients with ongoing participation in other clinical trials involving neurological interventions;\n* Inability to recognize the difference between the motor ON or OFF state;\n* Mild cognitive impairment or dementia;\n* Pregnancy.","ALL","18 Years",{"count":113,"type":114},130,"ESTIMATED","INTERVENTIONAL",[117],"NA","The objective of the CLOSE-PD study is to compare the efficacy of adaptive deep brain stimulation (aDBS) with continue deep brain stimulation (cDBS) in patients with Parkinson's disease. The main question it aims to answer is:\n\n\\- whether the change in daily mean ON time without troublesome dyskinesia in aDBS is greater than cDBS over a six-month follow-up period?\n\nResearchers will compare aDBS to regular continue deep brain stimulation (cDBS).\n\nParticipants will:\n\n* be set up to cDBS during the first programming visit (visit 2);\n* be randomized 1:1 to aDBS or cDBS two weeks after visit 2;\n* follow-up will be at three and six months after visit 2;\n* complete PD Home diary at baseline, two weeks, three months and at six months after visit 2.",[120,121],"Deep Brain Stimulation","Parkinson Disease",[123,124,125,126],"adaptive DBS","continue DBS","aDBS","cDBS","2026-01-28",{"date":129,"type":130},"2026-01-29","ACTUAL",{"date":132,"type":130},"2026-01-27",{"date":134,"type":114},"2027-02-01",{"name":5,"class":6},4]